Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw some unusual options trading activity on Wednesday. Investors purchased 37,151 call options on the stock. This represents an increase of approximately 42% compared to the typical daily volume of 26,190 call options.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $4.37, for a total value of $961,400.00. Following the completion of the sale, the director directly owned 6,869,863 shares in the company, valued at $30,021,301.31. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 8.43% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after purchasing an additional 4,149,346 shares during the period. Vanguard Group Inc. lifted its stake in shares of Recursion Pharmaceuticals by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after buying an additional 3,708,975 shares during the last quarter. Norges Bank bought a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $16,040,000. Nuveen LLC acquired a new position in Recursion Pharmaceuticals in the 1st quarter valued at about $10,118,000. Finally, Bank Pictet & Cie Europe AG acquired a new position in Recursion Pharmaceuticals in the 3rd quarter valued at about $7,954,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $4.44 on Friday. The company has a market cap of $2.31 billion, a PE ratio of -2.47 and a beta of 0.94. The firm has a 50-day moving average of $4.97 and a 200-day moving average of $5.13. Recursion Pharmaceuticals has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.Recursion Pharmaceuticals’s quarterly revenue was down 80.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.34) earnings per share. As a group, equities analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RXRX. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $10.00 to $11.00 in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Wednesday, October 8th. UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday. Finally, Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.